Breast Cancer Coverage from Every Angle

Helena M. Earl, MBBS, PhD: Is a Shorter Duration of Trastuzumab Effective in Early-Stage HER2-Positive Breast Cancer?

Posted: Tuesday, October 19, 2021

Helena M. Earl, MBBS, PhD, of the University of Cambridge, offers key insights into the rationale for a study she conducted on whether a duration of less than the standard of 12 months of adjuvant trastuzumab is noninferior for treatment outcomes in patients with HER2-positive early breast cancer. She also describes how clinicians should interpret the findings.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.